A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
about
Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysisS-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysisThe efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix.Effectiveness and safety profile of S-1-based chemotherapy compared with capecitabine-based chemotherapy for advanced gastric and colorectal cancer: A meta-analysis.Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma.Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis.Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy.S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysisA Meta-analysis Reveals S-1-based Chemotherapy Improves the Survival of Patients With Advanced Gastric Cancer.Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer.Chemotherapy for advanced gastric cancer.Capecitabine for the treatment of gastric cancer.S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis.The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan.Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis.CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients.Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study.Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer.S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study.Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review.Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107.Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel.The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status.Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer.A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer.Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI).Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer.
P2860
Q26865057-9756AF8A-BA68-49DA-A7E2-0148567F53E3Q27002415-8C93FEA6-B7D1-4E7F-A945-6E0748336DA9Q27318805-F0EBBAAF-C90C-4B1B-9CE3-8957C9F75CDCQ33406474-C7B7E273-371D-4C3B-956D-3ABC1B35E6C8Q33415971-E22B4DF4-E482-477D-8A65-4DA969A96C38Q33425150-ADD8F1F2-A5D1-4CA5-8AAC-E35EB1F57E2AQ33728364-BFEDD40D-36AB-4A1E-A160-4132DED89BD5Q33889328-9AF236FD-11A7-4FB3-A2EC-D933827BBE07Q34658209-1740BA6E-7D7C-4509-9088-A2FBD8D88759Q34897322-DDC51CDB-E3E1-4D47-BAA1-9FECF68CC2A6Q35060024-A7DFF5CD-81E7-4A39-94DB-AED511A9E98BQ35070531-60DE7A83-D47E-4E79-AC75-468E54183D24Q35083334-8280ADE7-295B-4CB6-8B69-89A024EBFB60Q35612770-4D5DF62E-D355-4365-B9F6-1FC85E8D0E47Q37561374-EFE9AF67-6DA8-4EB0-AC36-7B317023A63BQ38604012-FB019D3F-A5F9-450F-985C-B7CFC6F7798DQ38608072-26C9D31D-EF47-4899-B37A-8C671EEAF32DQ38619215-7F9FE2B9-8717-47D9-9431-B4DEE6D18F97Q38645852-ECD03B0B-91AD-4ADE-AEE5-7F6D0D4EBE79Q38941416-2B4B9D33-0E8F-4BE1-80D8-417E20EB67B3Q38986946-9DCAF378-052F-475D-AC5B-598EDAEEE9BAQ39096119-66E40F83-2DF4-44E9-9C4A-74CEE8F2E4B3Q39728271-5392A3A9-0857-42DA-8D79-DBF133578ED6Q42353453-5EB894C7-432B-4675-B095-598B4F88E712Q42378852-6292F474-5C14-48F5-8DDC-2CCC225E2A66Q43067439-F5963CAF-CDEA-4815-8B06-FEA227075A41Q44064732-F4D56E55-3B5C-457A-BC83-B14533A2B995Q48145007-74CF305C-77B2-464C-930B-7135BBA613EDQ50076031-5ED8E81D-E34A-4721-B7A2-A95A7A3A9054Q52597607-79A49066-2043-485A-8192-9382A6241B52Q53201331-A64E830B-C228-4CC7-B659-87A66518D7FFQ53560105-A683D7E9-3524-48C8-8B29-ADE5A8EDC311Q54645262-DBA35AB4-E5E0-40DC-A4A3-26A27EDD99FDQ55005321-5F6BF66D-6271-4AD7-A492-1D22A39E6933Q55222865-7972CA17-6FCB-47EB-9A3F-1C2D12ED1C6F
P2860
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A randomized phase II trial of ...... in in advanced gastric cancer.
@ast
A randomized phase II trial of ...... in in advanced gastric cancer.
@en
type
label
A randomized phase II trial of ...... in in advanced gastric cancer.
@ast
A randomized phase II trial of ...... in in advanced gastric cancer.
@en
prefLabel
A randomized phase II trial of ...... in in advanced gastric cancer.
@ast
A randomized phase II trial of ...... in in advanced gastric cancer.
@en
P2093
P50
P1476
A randomized phase II trial of ...... tin in advanced gastric cancer
@en
P2093
Byung Ho Nam
Gun Min Kim
Hei-Cheul Jeung
Hyo Song Kim
Kyung Hee Lee
P304
P356
10.1016/J.EJCA.2011.12.017
P577
2012-01-12T00:00:00Z